Anthony Petrone
Stock Analyst at Mizuho
(4.12)
# 515
Out of 5,124 analysts
210
Total ratings
54.55%
Success rate
11.47%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Neutral | $18 → $21 | $23.54 | -10.79% | 2 | Dec 17, 2025 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $6.40 | +56.25% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $64.12 | +12.29% | 10 | Dec 17, 2025 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $60 → $72 | $69.68 | +3.33% | 7 | Dec 17, 2025 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $110 → $130 | $97.21 | +33.73% | 7 | Dec 17, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $75 → $90 | $82.77 | +8.74% | 16 | Dec 17, 2025 | |
| GH Guardant Health | Maintains: Outperform | $100 → $120 | $112.33 | +6.83% | 4 | Dec 17, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $85 → $90 | $69.32 | +29.83% | 9 | Dec 17, 2025 | |
| DXCM DexCom | Maintains: Outperform | $75 → $78 | $69.89 | +11.60% | 3 | Dec 17, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $85 → $100 | $84.32 | +18.60% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $31.05 | +28.82% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $81.81 | +22.23% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $249.19 | +20.39% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $85.85 | +16.48% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $74.91 | +4.12% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $124.82 | +8.16% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $127.78 | +5.65% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $22.29 | -19.23% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $100.31 | -0.31% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $12.39 | -3.15% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $112.28 | +55.86% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.30 | +534.92% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $101.65 | -40.97% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $79.89 | -27.40% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $97.79 | +12.49% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $18.34 | -23.66% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $86.73 | +21.07% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $592.85 | -34.22% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $83.51 | -19.77% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $94.75 | +84.70% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $12.65 | +97.63% | 3 | May 13, 2020 |
Tandem Diabetes Care
Dec 17, 2025
Maintains: Neutral
Price Target: $18 → $21
Current: $23.54
Upside: -10.79%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $6.40
Upside: +56.25%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $64.12
Upside: +12.29%
Lantheus Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $69.68
Upside: +3.33%
Inspire Medical Systems
Dec 17, 2025
Maintains: Outperform
Price Target: $110 → $130
Current: $97.21
Upside: +33.73%
Haemonetics
Dec 17, 2025
Maintains: Outperform
Price Target: $75 → $90
Current: $82.77
Upside: +8.74%
Guardant Health
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $112.33
Upside: +6.83%
Establishment Labs Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $85 → $90
Current: $69.32
Upside: +29.83%
DexCom
Dec 17, 2025
Maintains: Outperform
Price Target: $75 → $78
Current: $69.89
Upside: +11.60%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $84.32
Upside: +18.60%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $31.05
Upside: +28.82%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $81.81
Upside: +22.23%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $249.19
Upside: +20.39%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $85.85
Upside: +16.48%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $74.91
Upside: +4.12%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $124.82
Upside: +8.16%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $127.78
Upside: +5.65%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $22.29
Upside: -19.23%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $100.31
Upside: -0.31%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $12.39
Upside: -3.15%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $112.28
Upside: +55.86%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $6.30
Upside: +534.92%
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $101.65
Upside: -40.97%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $79.89
Upside: -27.40%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $97.79
Upside: +12.49%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $18.34
Upside: -23.66%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $86.73
Upside: +21.07%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $592.85
Upside: -34.22%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $83.51
Upside: -19.77%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $94.75
Upside: +84.70%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $12.65
Upside: +97.63%